Evaluation of the efficacy of multiple myeloma therapy with VTD plus doxorubicin
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma / Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 141:(2008), pp. 814-819. [10.1111/j.1365-2141.2008.07147.x]
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
SANTINI, VALERIA;BOSI, ALBERTO
2008
Abstract
Evaluation of the efficacy of multiple myeloma therapy with VTD plus doxorubicin
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
